HPS Pharmacies wish to give notice that there is a supply interruption for nifedipine as follows:
|Product||ARTG||Expected Return Date|
|Adalat® Oros 20mg||60101||End June 2021|
|Adalat® Oros 30mg||76041||Early March 2021|
|Addos® XR 30mg||114825||Mid-late June 2020|
|APO-Nifedipine XR 30mg||152207||Mid-March 2020|
|Adefin® XL 30mg||91779||Discontinued|
|Adalat® Oros 60mg||76040||End-May 2021|
|Addos® XR 60mg||98806||Mid-late June 2020|
|Adefin® XL 60mg||91779||Discontinued|
|APO-Nifedipine XR 60mg||152208||Mid-March 2020|
Limited supplies of nifedipine 30mg modified-release tablets are currently available at some warehouses. An internationally registered brand of nifedipine 30mg modified-release tablets and nifedipine 60mg modified-release tablets has been approved for supply under Section 19A of the Therapeutic Goods Act 1989. Other presentations of nifedipine may be accessed via the Special Access Scheme (SAS) if necessary. Please note that SAS and Section 19A alternatives are subject to a longer lead-time and different pricing as they must be sourced internationally.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact your pharmacist at HPS Pharmacies.